» Articles » PMID: 31161257

PET Imaging of Distinct Brain Uptake of a Nanobody and Similarly-sized PAMAM Dendrimers After Intra-arterial Administration

Abstract

Introduction: We have recently shown that intracerebral delivery of an anti-VEGF monoclonal antibody bevacizumab using an intra-arterial (IA) infusion is more effective than intravenous administration. While antibodies are quickly emerging as therapeutics, their disadvantages such as large size, production logistics and immunogenicity motivate search for alternatives. Thus we have studied brain uptake of nanobodies and polyamidoamine (PAMAM) dendrimers.

Methods: Nanobodies were conjugated with deferoxamine (DFO) to generate NB(DFO). Generation-4 PAMAM dendrimers were conjugated with DFO, and subsequently primary amines were capped with butane-1,2-diol functionalities to generate G4(DFO)(Bdiol). Resulting conjugates were radiolabeled with zirconium-89. Brain uptake of ZrNB(DFO) and ZrG4(DFO)(Bdiol) upon carotid artery vs tail vein infusions with intact BBB or osmotic blood-brain barrier opening (OBBBO) with mannitol in mice was monitored by dynamic positron emission tomography (PET) over 30 min to assess brain uptake and clearance, followed by whole-body PET-CT (computed tomography) imaging at 1 h and 24 h post-infusion (pi). Imaging results were subsequently validated by ex-vivo biodistribution.

Results: Intravenous administration of ZrNB(DFO) and ZrG4(DFO)(Bdiol) resulted in their negligible brain accumulation regardless of BBB status and timing of OBBBO. Intra-arterial (IA) administration of ZrNB(DFO) dramatically increased its brain uptake, which was further potentiated with prior OBBBO. Half of the initial brain uptake was retained after 24 h. In contrast, IA infusion of ZrG4(DFO)(Bdiol) resulted in poor initial accumulation in the brain, with complete clearance within 1 h of administration. Ex-vivo biodistribution results reflected those on PET-CT.

Conclusions: IA delivery of nanobodies might be an attractive therapeutic platform for CNS disorders where prolonged intracranial retention is necessary.

Citing Articles

Preparation and Application of Alpha Toxin Nanobodies.

Jia Q, Ren H, Zhang S, Yang H, Gao S, Fan R Vet Sci. 2024; 11(8).

PMID: 39195835 PMC: 11360521. DOI: 10.3390/vetsci11080381.


Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review.

Medina Perez V, Baselga M, Schuhmacher A Cancers (Basel). 2024; 16(15).

PMID: 39123409 PMC: 11311928. DOI: 10.3390/cancers16152681.


Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management.

Cong Y, Devoogdt N, Lambin P, Dubois L, Yaromina A Cancers (Basel). 2024; 16(2).

PMID: 38254860 PMC: 10814765. DOI: 10.3390/cancers16020371.


Functionalized Nanomaterials Capable of Crossing the Blood-Brain Barrier.

Zha S, Liu H, Li H, Li H, Wong K, All A ACS Nano. 2024; 18(3):1820-1845.

PMID: 38193927 PMC: 10811692. DOI: 10.1021/acsnano.3c10674.


Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy.

Babamohamadi M, Mohammadi N, Faryadi E, Haddadi M, Merati A, Ghobadinezhad F Cell Death Dis. 2024; 15(1):17.

PMID: 38191571 PMC: 10774412. DOI: 10.1038/s41419-023-06391-x.


References
1.
Van den Abbeele A, De Clercq S, De Ganck A, De Corte V, Van Loo B, Soror S . A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction. Cell Mol Life Sci. 2010; 67(9):1519-35. PMC: 11115616. DOI: 10.1007/s00018-010-0266-1. View

2.
Boockvar J, Tsiouris A, Hofstetter C, Kovanlikaya I, Fralin S, Kesavabhotla K . Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg. 2010; 114(3):624-32. PMC: 3622705. DOI: 10.3171/2010.9.JNS101223. View

3.
Vaidyanathan G, McDougald D, Choi J, Koumarianou E, Weitzel D, Osada T . Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. J Nucl Med. 2016; 57(6):967-73. PMC: 4891273. DOI: 10.2967/jnumed.115.171306. View

4.
Bannas P, Lenz A, Kunick V, Well L, Fumey W, Rissiek B . Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection. Contrast Media Mol Imaging. 2015; 10(5):367-78. DOI: 10.1002/cmmi.1637. View

5.
Samec N, Jovcevska I, Stojan J, Zottel A, Liovic M, Myers M . Glioblastoma-specific anti-TUFM nanobody for immunoimaging and cancer stem cell targeting. Oncotarget. 2018; 9(25):17282-17299. PMC: 5915116. DOI: 10.18632/oncotarget.24629. View